The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Chemotherapy Drugs for Neuroblastoma Market Research Report 2024

Global Chemotherapy Drugs for Neuroblastoma Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1744126

No of Pages : 91

Ask Your Query

Synopsis
Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.

Global Chemotherapy Drugs for Neuroblastoma market is projected to reach US$ 167.6 million in 2029, increasing from US$ 123 million in 2022, with the CAGR of 4.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Chemotherapy Drugs for Neuroblastoma market research.

Key manufacturers engaged in the Chemotherapy Drugs for Neuroblastoma industry include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi and Accord Healthcare, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Chemotherapy Drugs for Neuroblastoma were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Chemotherapy Drugs for Neuroblastoma market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Chemotherapy Drugs for Neuroblastoma market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Baxter Healthcare
  • Ingenus Pharmaceuticals
  • ANI Pharmaceuticals
  • Teva Pharmaceuticals
  • Qilu Pharmaceutical
  • Pfizer
  • Hikma Pharmaceuticals
  • Fresenius Kabi
  • Accord Healthcare
  • Viatris

Segment by Type

  • Cyclophosphamide
  • Cisplatin or Carboplatin
  • Vincristine
  • Doxorubicin (Adriamycin)
  • Etoposide
  • Other

Segment by Application

  • Hospital
  • Clinic
  • Other

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Chemotherapy Drugs for Neuroblastoma report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Chemotherapy Drugs for Neuroblastoma Market Overview
1.1 Product Overview and Scope of Chemotherapy Drugs for Neuroblastoma
1.2 Chemotherapy Drugs for Neuroblastoma Segment by Type
1.2.1 Global Chemotherapy Drugs for Neuroblastoma Market Value Comparison by Type (2023-2029)
1.2.2 Cyclophosphamide
1.2.3 Cisplatin or Carboplatin
1.2.4 Vincristine
1.2.5 Doxorubicin (Adriamycin)
1.2.6 Etoposide
1.2.7 Other
1.3 Chemotherapy Drugs for Neuroblastoma Segment by Application
1.3.1 Global Chemotherapy Drugs for Neuroblastoma Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Chemotherapy Drugs for Neuroblastoma Market Size Estimates and Forecasts
1.4.1 Global Chemotherapy Drugs for Neuroblastoma Revenue 2018-2029
1.4.2 Global Chemotherapy Drugs for Neuroblastoma Sales 2018-2029
1.4.3 Global Chemotherapy Drugs for Neuroblastoma Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Chemotherapy Drugs for Neuroblastoma Market Competition by Manufacturers
2.1 Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Manufacturers (2018-2023)
2.2 Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Chemotherapy Drugs for Neuroblastoma Average Price by Manufacturers (2018-2023)
2.4 Global Chemotherapy Drugs for Neuroblastoma Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Chemotherapy Drugs for Neuroblastoma, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Chemotherapy Drugs for Neuroblastoma, Product Type & Application
2.7 Chemotherapy Drugs for Neuroblastoma Market Competitive Situation and Trends
2.7.1 Chemotherapy Drugs for Neuroblastoma Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Chemotherapy Drugs for Neuroblastoma Players Market Share by Revenue
2.7.3 Global Chemotherapy Drugs for Neuroblastoma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Chemotherapy Drugs for Neuroblastoma Retrospective Market Scenario by Region
3.1 Global Chemotherapy Drugs for Neuroblastoma Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Chemotherapy Drugs for Neuroblastoma Global Chemotherapy Drugs for Neuroblastoma Sales by Region: 2018-2029
3.2.1 Global Chemotherapy Drugs for Neuroblastoma Sales by Region: 2018-2023
3.2.2 Global Chemotherapy Drugs for Neuroblastoma Sales by Region: 2024-2029
3.3 Global Chemotherapy Drugs for Neuroblastoma Global Chemotherapy Drugs for Neuroblastoma Revenue by Region: 2018-2029
3.3.1 Global Chemotherapy Drugs for Neuroblastoma Revenue by Region: 2018-2023
3.3.2 Global Chemotherapy Drugs for Neuroblastoma Revenue by Region: 2024-2029
3.4 North America Chemotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.4.1 North America Chemotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Chemotherapy Drugs for Neuroblastoma Sales by Country (2018-2029)
3.4.3 North America Chemotherapy Drugs for Neuroblastoma Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Chemotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.5.1 Europe Chemotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Chemotherapy Drugs for Neuroblastoma Sales by Country (2018-2029)
3.5.3 Europe Chemotherapy Drugs for Neuroblastoma Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Chemotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.6.1 Asia Pacific Chemotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Chemotherapy Drugs for Neuroblastoma Sales by Country (2018-2029)
3.6.3 Asia Pacific Chemotherapy Drugs for Neuroblastoma Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Chemotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.7.1 Latin America Chemotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Chemotherapy Drugs for Neuroblastoma Sales by Country (2018-2029)
3.7.3 Latin America Chemotherapy Drugs for Neuroblastoma Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Chemotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.8.1 Middle East and Africa Chemotherapy Drugs for Neuroblastoma Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Chemotherapy Drugs for Neuroblastoma Sales by Country (2018-2029)
3.8.3 Middle East and Africa Chemotherapy Drugs for Neuroblastoma Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Chemotherapy Drugs for Neuroblastoma Sales by Type (2018-2029)
4.1.1 Global Chemotherapy Drugs for Neuroblastoma Sales by Type (2018-2023)
4.1.2 Global Chemotherapy Drugs for Neuroblastoma Sales by Type (2024-2029)
4.1.3 Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Type (2018-2029)
4.2 Global Chemotherapy Drugs for Neuroblastoma Revenue by Type (2018-2029)
4.2.1 Global Chemotherapy Drugs for Neuroblastoma Revenue by Type (2018-2023)
4.2.2 Global Chemotherapy Drugs for Neuroblastoma Revenue by Type (2024-2029)
4.2.3 Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2018-2029)
4.3 Global Chemotherapy Drugs for Neuroblastoma Price by Type (2018-2029)
5 Segment by Application
5.1 Global Chemotherapy Drugs for Neuroblastoma Sales by Application (2018-2029)
5.1.1 Global Chemotherapy Drugs for Neuroblastoma Sales by Application (2018-2023)
5.1.2 Global Chemotherapy Drugs for Neuroblastoma Sales by Application (2024-2029)
5.1.3 Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Application (2018-2029)
5.2 Global Chemotherapy Drugs for Neuroblastoma Revenue by Application (2018-2029)
5.2.1 Global Chemotherapy Drugs for Neuroblastoma Revenue by Application (2018-2023)
5.2.2 Global Chemotherapy Drugs for Neuroblastoma Revenue by Application (2024-2029)
5.2.3 Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Application (2018-2029)
5.3 Global Chemotherapy Drugs for Neuroblastoma Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Baxter Healthcare
6.1.1 Baxter Healthcare Corporation Information
6.1.2 Baxter Healthcare Description and Business Overview
6.1.3 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.1.5 Baxter Healthcare Recent Developments/Updates
6.2 Ingenus Pharmaceuticals
6.2.1 Ingenus Pharmaceuticals Corporation Information
6.2.2 Ingenus Pharmaceuticals Description and Business Overview
6.2.3 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.2.5 Ingenus Pharmaceuticals Recent Developments/Updates
6.3 ANI Pharmaceuticals
6.3.1 ANI Pharmaceuticals Corporation Information
6.3.2 ANI Pharmaceuticals Description and Business Overview
6.3.3 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.3.4 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.3.5 ANI Pharmaceuticals Recent Developments/Updates
6.4 Teva Pharmaceuticals
6.4.1 Teva Pharmaceuticals Corporation Information
6.4.2 Teva Pharmaceuticals Description and Business Overview
6.4.3 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.4.5 Teva Pharmaceuticals Recent Developments/Updates
6.5 Qilu Pharmaceutical
6.5.1 Qilu Pharmaceutical Corporation Information
6.5.2 Qilu Pharmaceutical Description and Business Overview
6.5.3 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.5.5 Qilu Pharmaceutical Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Pfizer Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Hikma Pharmaceuticals
6.6.1 Hikma Pharmaceuticals Corporation Information
6.6.2 Hikma Pharmaceuticals Description and Business Overview
6.6.3 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.7.5 Hikma Pharmaceuticals Recent Developments/Updates
6.8 Fresenius Kabi
6.8.1 Fresenius Kabi Corporation Information
6.8.2 Fresenius Kabi Description and Business Overview
6.8.3 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.8.5 Fresenius Kabi Recent Developments/Updates
6.9 Accord Healthcare
6.9.1 Accord Healthcare Corporation Information
6.9.2 Accord Healthcare Description and Business Overview
6.9.3 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.9.5 Accord Healthcare Recent Developments/Updates
6.10 Viatris
6.10.1 Viatris Corporation Information
6.10.2 Viatris Description and Business Overview
6.10.3 Viatris Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Viatris Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.10.5 Viatris Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Chemotherapy Drugs for Neuroblastoma Industry Chain Analysis
7.2 Chemotherapy Drugs for Neuroblastoma Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Chemotherapy Drugs for Neuroblastoma Production Mode & Process
7.4 Chemotherapy Drugs for Neuroblastoma Sales and Marketing
7.4.1 Chemotherapy Drugs for Neuroblastoma Sales Channels
7.4.2 Chemotherapy Drugs for Neuroblastoma Distributors
7.5 Chemotherapy Drugs for Neuroblastoma Customers
8 Chemotherapy Drugs for Neuroblastoma Market Dynamics
8.1 Chemotherapy Drugs for Neuroblastoma Industry Trends
8.2 Chemotherapy Drugs for Neuroblastoma Market Drivers
8.3 Chemotherapy Drugs for Neuroblastoma Market Challenges
8.4 Chemotherapy Drugs for Neuroblastoma Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock